Product Reports Resources Pricing Login Book a demo

Circe Biosciences

Energy · Boston, United States · Founded 2021

Developing a manufacturing platform capable of producing any organic molecule using carbon dioxide, water, and electricity MoreLess

Circe Biosciences, Inc. operates at the intersection of synthetic biology and decarbonization, developing a manufacturing platform that transforms carbon dioxide into a variety of valuable chemicals. The company was co-founded by Shannon Nangle and Marika Ziesack, who both bring extensive experience from the Wyss Institute for Biologically Inspired Engineering at Harvard University. Their collective background in gas fermentation and synthetic biology underpins the company's core technology. The process leverages gas fermentation, utilizing microbes that consume greenhouse gases like carbon dioxide, along with water and electricity, to produce a range of organic molecules.

The primary goal is to provide a sustainable alternative to traditional petrochemical-based manufacturing, thereby reducing the carbon footprint of numerous industries. Circe Biosciences' platform is designed to create products such as triglycerides for food production, bioplastics, and other specialty chemicals. This approach targets industries reliant on these materials, offering them a method to decarbonize their supply chains. The business model appears to be centered on producing and selling these sustainably sourced molecules or potentially licensing the technology to large-scale manufacturing partners. By converting a waste product (CO2) into essential goods, the company aims to build a more resilient and circular economy.

The company's platform functions by engineering microbes to be highly efficient at converting CO2 into specific target molecules. This fermentation process is positioned as a direct competitor to conventional methods that rely on fossil fuels. Significant milestones include securing a $1 million investment from The Engine, a venture firm with roots at MIT, which has provided crucial early-stage support. The company has also been recognized through various awards, including participation in the 2022 cohort of the Third Derivative accelerator program, underscoring its potential impact on climate technology. This technology offers the benefit of producing familiar products through a fundamentally different and more environmentally friendly pathway.

Keywords: gas fermentation, carbon capture, synthetic biology, decarbonization, sustainable manufacturing, alternative proteins, biochemicals, climate tech, circular economy, industrial biotechnology

Company overview

Circe Biosciences company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2021
Headquarters
Boston, United States
Employees
51
Open positions
None listed
Dealroom signal
61.6
client focusb2btechnologyHardwaretechnologyDeep Techsub industryClean Energysub industryInnovative Foodbusiness modelManufacturingsectorBiotechnologysectorSpinoutsectorSustainable Development GoalssectorFermentationsectorBiotechnology in FoodsectorClimate TechsectorAlternative Fats and OilssectorDT and LS

Valuation & funding

Circe Biosciences funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEEDEquity / VC Sep 2024 $5M $40M Bee Partners · Ponderosa Ventures · ReGen Ventures · Safar Partners
EARLY VCEquity / VC May 2024 $8M $32M Bee Partners · Undeterred Capital · ReGen Ventures · Elementum Ventures
SUPPORT PROGRAMOther financing Oct 2021 $0 Activate
SPINOUTOther financing Oct 2021 $0 Harvard University · Wyss Institute
GRANTOther financing May 2021 $3M ARPA-E
Showing 5 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

YearEmployees
2026 51
2025 51
2024 39
2023 43
2022 13
2021 3
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Circe Biosciences website traffic

Latest recorded traffic for Circe Biosciences is 410 monthly website visits, down 48.1% over the last three months. Circe Biosciences's team grew 0% over the past year.

Latest monthly visits410 3-month web change-48.1% 1-year team growth0%
Monthly website visits45 observations · Oct 2022–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Circe Biosciences compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Circe Biosciences's talent

Book a demo to see the people
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

13 investors on Circe Biosciences's cap table

Sourced from Dealroom's funding and investor records.

Seed 4 investors entered at this stage
ARPA-E
Safar Partners
Exceptional Ventures
Climate Capital
Series A 5 investors entered at this stage
Bee Partners
Undeterred Capital
ReGen Ventures
Elementum Ventures
Ponderosa Ventures
Other known 4 additional known investors
Activate
Harvard University
Wyss Institute
Juniper

Global footprint

Where Circe Biosciences has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States85.7%
🇦🇺 Australia14.3%
2 countries shown

In the news

Latest news about Circe Biosciences

Recent press, funding announcements, and product moves mentioning Circe Biosciences — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Circe Biosciences

An AI-synthesized read of the highest-engagement posts about Circe Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Circe Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.